Mark W. Hahn - 26 Sep 2022 Form 4 Insider Report for Verona Pharma plc (VRNA)

Role
Chief Financial Officer
Signature
/s/ Claire Poll, Attorney-in-fact for Mark Hahn
Issuer symbol
VRNA
Transactions as of
26 Sep 2022
Net transactions value
$0
Form type
4
Filing time
28 Sep 2022, 16:06:18 UTC
Previous filing
11 Aug 2022
Next filing
03 Nov 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VRNA Ordinary Shares Award $0 +3,600,000 +25% $0.000000 17,913,496 26 Sep 2022 Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer.
F2 Represents an award of Restricted Share Units ("RSUs"), each of which represents a contingent right to receive one (1) Ordinary Share of the Issuer. The RSUs vest over four years, with 900,000 RSUs vesting on November 1, 2023 and the balance vesting in 12 equal quarterly installments thereafter.
F3 Consists of (i) 10,602,376 Ordinary Shares underlying RSUs (which are represented by 1,325,297 ADSs); and (ii) 7,311,120 Ordinary Shares underlying 913,890 ADSs.